Royalty Audits on China License Deals: When Sales Live in WeChat and Tender Files

Life Sciences & Healthcare Blog · Legal cluster

Royalty clauses assume enterprise-resource-planning (ERP) truth: every sale appears in the licensee's system, every discount is recorded, and the royalty report is a faithful digest of the ledger. China's pharmaceutical and biotech channel reality is different — tender shipments, distributor transfers, provincial procurement-platform awards, and WeChat deal chat that never reaches the royalty report. This article explains how a licensor structures audit rights, net-sales definitions, and record-keeping obligations so that a royalty audit of a China licensee actually finds the sales, and where the contract tools must reach — including third-party distributors and related parties — to keep the licence economics honest.

Why this matters: the royalty base is where licence deals lose value#

In China licence-in and licence-out transactions, royalties are usually the largest component of deal value after milestones. The licensor grants rights to a product, the licensee sells it through a distribution channel that includes hospitals, provincial tender platforms, chain pharmacies, and increasingly online and specialty channels — and the royalty report describes those sales in aggregate. If the report misses sales, the licence underperforms silently: the licensor is paid on a fiction while the licensee's distributors generate real revenue outside the royalty base.

The problem is structural, not malicious. Chinese distribution runs through layers: the licensee sells to distributors, distributors sell to hospitals and pharmacies, and tender awards are recorded on provincial platforms. A licensor that audits only the licensee's ERP sees the first layer. The gap between the first layer and the final sale to the patient — the distributor's onward sales, the tender-award volumes, the WeChat-negotiated deals — is where value leaks. This article focuses on the contract tools that pull the audit all the way down the chain.

Governing legal and statutory framework#

PRC Civil Code — Contract Book#

The licence agreement is a contract under the Civil Code of the People's Republic of China, and its audit-rights, reporting, and definitional clauses are enforceable as agreed. The Civil Code's contract provisions give the parties freedom to define the royalty base, the audit mechanism, and the consequences of underreporting — but only if the contract actually says what the parties intend. A clause that says "audit rights" without reaching distributors, or defines "net sales" without addressing VBP discounts, is a contract that looks protective and is not.

PRC Anti-Monopoly Law (2022 amendment) — Article 18#

Article 18 of the amended Anti-Monopoly Law addresses resale price maintenance and vertical agreements. For licence deals, this matters because a licensee that controls distributor resale prices — to preserve margin after paying royalties — may create a vertical monopoly-agreement exposure for itself. The licensor's audit of the distribution chain should therefore be aware of how the licensee's channel controls distributors, because a channel built on RPM is both an antitrust problem for the licensee and a distraction in the royalty file.

Anti-Monopoly Law of the People's Republic of China (2022), Article 18: An undertaking shall not fix resale prices with its trading counterparties... An agreement fixing the minimum resale price... shall be presumed to be a monopoly agreement... unless the undertaking can prove that the agreement falls within one of the statutory exemptions.

Enterprise Income Tax withholding rules for cross-border royalty payments#

Where the licensor is offshore, royalty payments from the Chinese licensee are subject to PRC enterprise income tax withholding and, for non-resident enterprises, value-added tax on the royalty income. The tax treatment of royalties interacts with the audit: a licensor that asserts a higher royalty base through audit may need to reconcile the additional amounts with the withholding filings, and the licensee's withholding compliance is itself an audit item. The royalty audit is therefore not only a commercial reconciliation; it touches the tax file on both sides.

Key legal analysis and enforcement precedents#

Chinese arbitration practice has produced a consistent record on royalty disputes. Tribunals — including under the China International Economic and Trade Arbitration Commission (CIETAC) — have examined royalty-calculation disputes where the licensee's reported sales diverged from the channel evidence: tender-award records, distributor purchase records, and even sales conducted through messaging applications and informal channels. The recurring question in those cases is evidentiary: what records prove the true volume of sales? Where the contract required structured records and the licensee kept none, tribunals have drawn adverse inferences and adjusted the royalty base. Where the audit rights did not reach the distributor layer, the licensor was left arguing about numbers it could not verify — a losing position in any forum.

The lessons from those decisions for contract drafting are concrete. First, audit rights that stop at the licensee are structurally insufficient for a China channel. Second, "net sales" definitions that ignore VBP discounts, free goods, and chargebacks create ambiguity that the party with the records wins. Third, the absence of a record-keeping obligation — "WeChat alone is not a system of record" — makes the royalty base unverifiable and invites the tribunal to resolve doubt against the party that failed to keep records. The contract must create the evidence before the dispute exists.

Related-party leakage is the fourth theme. Where the licensee's sales run through related distributors, the pricing between the licensee and the related party is a transfer-pricing question: the Enterprise Income Tax Law requires related-party transactions to reflect arm's-length pricing, and a related distributor priced to keep royalties low is both a royalty dispute and a tax adjustment waiting to happen. The audit should test related-party prices as part of the royalty review.

The definition of "net sales" is the clause that most licence disputes in China actually turn on, and the gap is usually in the treatment of the procurement channel. Provincial volume-based procurement sets prices that are a fraction of list price, and the royalty clause frequently fails to state whether the procurement price is the royalty base or whether a list-price floor applies. The same ambiguity affects online sales, where platform fees and discounts are layered onto the price. The drafting fix is not a single sentence; it is a schedule that defines the sales channel, the price each channel contributes to the base, and the deductions that are and are not allowed, so that the royalty report and the channel evidence can be reconciled line by line.

Operational vulnerabilities and transactional pitfalls#

• Audit rights confined to the licensee WFOE: the contract gives the licensor access to the licensee's books but not to the distributor's records, and the distributor is where the sales actually happened.
• Net-sales ambiguity under VBP: VBP procurement sets prices far below list price, and the royalty clause's "net sales" definition may not state whether VBP volumes are included, at what price, and whether procurement-platform fees reduce the base. The ambiguity is worth real money.
• Free goods and chargebacks: promotional free goods, patient-assistance programmes, and distributor chargebacks are treated inconsistently, and each inconsistency leaks from the royalty base.
• WeChat as the system of record: sales, discounts, and tender discussions happen in WeChat, and the licensee keeps no structured record of them. The royalty report is built on ERP; the real deal lives in chat.
• Related-party pricing: the licensee sells through a related distributor at low transfer prices, reducing the royalty base while the related party books the margin. The licensor's audit never reaches the related-party prices, and the tax authority would if it looked.
• Post-termination gap: audit rights expire with the agreement, and the licensee's obligations to report run out just when the licensor most needs to reconcile final sales.

Enforcement-side notes from Shenzhen on the royalty base#

In my life-sciences enforcement-response practice in Shenzhen, I see the royalty dispute from the side of the file that gets tested: the licence agreement, the royalty reports, the audit findings and the channel records that a tribunal or regulator will compare. The consistent failure is the gap between the report and the channel. The audit right confined to the licensee’s WFOE is the classic drafting error — the contract gives the licensor access to the licensee’s books but not to the distributor’s records, and the distributor is where the sales actually happened. The net-sales ambiguity under VBP is the second: procurement prices sit far below list price, and the royalty clause’s definition may not state whether VBP volumes are included, at what price, and whether procurement-platform sales count. The WeChat layer is the third: sales conducted through messaging applications and informal channels live outside the record-keeping obligation unless the contract and the compliance programme bring them in. My advice to licensors is to draft the audit rights to reach the chain — distributors, sub-distributors and related parties, with a contractual obligation on the licensee to procure their cooperation — and to verify the base below the first layer before termination, because the audit rights you thought you had may expire with the agreement. In royalty disputes, the party with the evidence below the first layer wins; the contract that reaches the chain is the evidence plan.

Strategic compliance roadmap and action plan#

Build the royalty architecture in the contract, then verify it in the field:

1. Draft audit rights that reach the chain: the licensor's audit right extends expressly to the licensee's distributors, sub-distributors, and related parties, with a contractual obligation on the licensee to procure the cooperation of each — including the right to inspect tender-award records, hospital delivery notes, and procurement-platform data.
2. Define net sales with China channel specifics: the definition states how VBP volumes are priced into the base, whether free goods and patient-assistance programmes reduce the base and how, how chargebacks and rebates are treated, and that procurement-platform fees do not reduce the base unless expressly agreed.
3. Impose a record-keeping obligation: the licensee must maintain structured records of all sales — including WeChat-discussed deals, tender awards, and distributor transfers — in a format the auditor can verify. "WeChat alone" is expressly disclaimed as a system of record.
4. Test related-party prices: the audit includes a transfer-pricing review of the licensee's sales to related distributors, benchmarking the prices against arm's-length standards under the Enterprise Income Tax Law, so that royalties cannot be drained through related-party margins.
5. Extend audit survival: audit rights survive termination for a defined lookback period (typically three years), covering the reconciliation of final sales and any post-termination sell-through.

In the field, the audit posture is: reconcile tender-award volumes to shipments to royalty reports, sample hospital delivery notes at the distributor level, test related-party transfer prices, and bring bilingual auditors who understand the fapiao (special VAT invoice) chain — because in China the invoice chain is the transaction record that ERP alone will never show.

The audit programme should also define the consequences of underreporting in the contract, because the remedy shapes the licensee's incentives. Typical terms include interest on the underpaid royalty, the licensee's obligation to bear the reasonable cost of the audit where underreporting exceeds a defined margin, and termination rights for material breach. The agreed remedy should be commercially reasonable — a punitive overreach can be challenged, while a term that merely restates the obvious gives the licensee little reason to keep better records. The goal is not to threaten; it is to create the documentation incentive so that the audit, when it happens, reconciles cleanly instead of becoming the forum where years of channel reality surface for the first time.

What not to do#

Do not rely on a royalty report that no one has verified below the first layer. Do not accept "the licensee cooperates fully" as a substitute for contractual audit rights that reach distributors. Do not let WeChat deals live outside the record-keeping obligation. And do not discover after termination that the audit rights you thought you had expired with the agreement. In royalty disputes, the party with the evidence wins — the contract is the tool that creates the evidence before the dispute exists.

Read next: License-in/out milestones · VBP

Cluster: Life sciences legal hub · Life sciences blog